Clinical trialPhase 2Terminated
PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer
A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma
- Outcome
- Stopped earlySafety (Toxicity)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 3 January 2017
- Expected end
- 31 August 2018
- Enrollment
- 4 participants
- Sites
- 1
- Primary outcomes
- Number of Participants with Treatment Related Adverse Events (AEs)
- Sponsor
- Other
- Results posted
- No
- Last update
- 11 April 2019
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try